Drugmaker Pfizer, the first company to get U.S. emergency use authorization for a COVID-19 vaccine, swing to a small profit in the fourth-quarter as it started shipping vaccine doses. Pfizer said it expects roughly $15 billion this year in revenue from the two-dose vaccine. It won emergency clearance in mid-December from U.S. regulators and continues to stack up approvals in other countries, and is in high demand as the global pandemic surges. On Tuesday, Pfizer reported fourth-quarter net income of $594 million, or 10 cents per share. Adjusted earnings came to 42 cents per share, or 4 cents shy of Wall Street projections.
